August 2022

Jazz Pharmaceuticals

Innovating to Transform the Lives of Patients and Their Families

Casey
Xywav patient

Jazz Pharmaceuticals

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements related to: the Company's strategy to maximize the value of Xywav in IH and narcolepsy, expectations that Xywav will be the treatment of choice in 2023; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: management's assumptions and estimates regarding Xywav adoption in narcolepsy and IH; the timing of launch of Xyrem authorized generic products (AG Products) and generic versions of sodium oxybate and the level of AG Product royalties to the Company, the safety and efficacy profiles of competitive product launch(es) in narcolepsy and IH, and estimates of the size of the eligible IH patient population for Xywav obtaining and maintaining adequate coverage and reimbursement for the Company's products; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and future filings and reports by the Company including the Company's Quarterly Report on Form10-Q for the quarter ended June 30, 2022.

Oxybate: Durable, Long-lived Value Driver

Oxybate History

XYREM® (sodium oxybate) oral solution CIII

Over more than 15 years Jazz has:

- Established oxybate therapy as the standard of care in narcolepsy
- Established and operated a robust, FDA approved REMS and distribution system
- Built trust and strong relationships with narcolepsy HCPs and patient communities
- Provided patient support programs, including access
- Invested to significantly improve oxybate therapy based on stakeholder feedback

The Future of Oxybate

xywav™

Existing Narcolepsy Market

- ~7,550[1] narcolepsy patients taking Xywav exiting 2Q22
- Xyrem patients continuing to adopt Xywav

+

New Narcolepsy Patients

- Majority of new-to-oxybate patients being prescribed Xywav
- Opportunity to add patients previously not prescribed Xyrem based on sodium concerns

+

Idiopathic Hypersomnia

- ~1,150[1] IH patients taking Xywav exiting 2Q22
- No other FDA approved treatments

+

XYREM®

- Meaningful future royalties on Xyrem AGs

Expect Xywav to be the oxybate therapy of choice in 2023

FDA = Food & Drug Administration, IH = idiopathic hypersomnia, HCP = healthcare provider, REMS = Risk Evaluation and Mitigation Strategy, AGs = Authorized generics. [1]Xywav patients as of June 30, 2022.

Xywav in Narcolepsy: Continue Education on Life-long Burden of High Sodium Intake

xywav™

- Xywav contains **92% less sodium** than Xyrem
- Phase 3 trial demonstrated **highly statistically significant differences** compared to placebo in the primary endpoint (measuring the change in the weekly number of cataplexy attacks) and the key secondary endpoint (measuring the change in Epworth Sleepiness Scale (ESS) scores)
- Cardiovascular (CV) and cardio-metabolic diseases/disorders **are more common in patients with narcolepsy vs controls without narcolepsy**

In connection with granting ODE, FDA stated,
"**Xywav is clinically superior to Xyrem by means of greater safety** because Xywav provides a **greatly reduced chronic sodium burden** compared to Xyrem."

FDA's summary also stated,
"**The differences in the sodium content** of the two products at the recommended doses **will be clinically meaningful in reducing cardiovascular morbidity** in a substantial proportion of patients for whom the drug is indicated."

Xywav in IH: Indication Expansion Creates Growth Opportunity

xywav™

- IH is a neurologic sleep disorder characterized by **excessive daytime sleepiness, severe sleep inertia, cognitive impairment and prolonged, non-restorative night-time sleep**
- **Distinct symptomatology and diagnostic criteria** from other sleep disorders
- Sleep disorders **can negatively impact every facet of someone's life**

"***Idiopathic hypersomnia is a life-long condition**, and the approval of **Xywav will be instrumental in providing treatment** for symptoms such as excessive sleepiness and difficulty waking, **and in effectively managing this debilitating disorder**."*

Eric Bastings, M.D., Deputy Director of the Office of Neuroscience, FDA Center for Drug Evaluation and Research

First And Only FDA-approved Therapy To Treat IH[1]

- Received Orphan Drug Exclusivity (ODE) in IH
- ~37,000 patients in the U.S. diagnosed & actively seeking healthcare
- Potential overall U.S. patient population: 70,000 – 80,000 patients
- Efficient launch with >90% overlap with existing sleep call universe
- ~90% commercial coverage

IH = idiopathic hypersomnia, FDA = Food and Drug Administration, MOA = mechanism of action. [1]Xywav is approved for the treatment of IH in adults

Xywav Meaningfully Improved IH Patient Symptoms

Robust Phase 3 Trial Data

- Clinically meaningful and **statistically significant results** across primary and key secondary endpoints
- Objective and patient-reported measures demonstrated **clinically meaningful results**
- **57%** of participants taking wake promoting agents

Indicated To Treat IH In Adults

- **Broad label** rather than focus on specific symptomatology

xywav™

Epworth Sleepiness Scale[1]



Idiopathic Hypersomnia Severity Scale[1]



LXB = lower-sodium oxybate, D = day, DB = double-blind, DBRWP = double-blind randomized withdrawal period, ESS = Epworth Sleepiness Scale, IH = idiopathic hypersomnia, IHSS = Idiopathic Hypersomnia Severity Scale, OL = open label, OLE = open-label extension period, OLT = open-label titration and optimization period, SDP = stable-dose period, W = week.
[1]Data on file, this subgroup analysis was outside of the statistical hierarchy, n numbers vary across timepoints.

Executing Successful Xywav Launches

Active Xywav Patients[1]

Strong adoption with addition of ~900 active patients, across both indications, in each of the last four quarters



Total Oxybate: 17,100 average active oxybate patients on therapy as of 2Q22

- ✓ **Achieved significant milestone** in 2Q22, with **more** active oxybate **patients** taking **Xywav** than Xyrem
- ✓ **Achieved ~90%** of commercial lives covered for both indications

Xywav Narcolepsy: Continue to establish the importance of low sodium

- ✓ **7,550** active patients exiting 2Q22
  - Clinical superiority to Xyrem – FDA ODE
  - Positive transition experience for HCPs and patients

Xywav IH: Continued robust launch momentum

- ✓ **1,150** active patients exiting 2Q22
  - FDA ODE granted
  - Support patient initiation and access programs

HCP = healthcare provider, IH = idiopathic hypersomnia, ODE = Orphan Drug Exclusivity. [1]Approximate active Xywav patients exiting quarter.